In this week’s video, Dr. Brian G.M. Durie explains the somewhat confusing results of the IFM 2009 trial.

BOTTOM LINE:

With longer follow-up, the IFM 2009 trial may be able to demonstrate longer overall survival of patients in the transplant group.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
What are the prospects for early diagnosis, CRISPR gene-editing, and CAR T-cell therapies in myeloma?
Next Post
Should patients with light chain myeloma be more wary of disease outcomes than those with other types of myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.